Literature DB >> 18635345

Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit.

Srikumar Mallick1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is the commonest cause of interstitial lung disease. Till date there is no proven successful treatment. The prognosis is poor with a median survival of 3 years. Patients with IPF presented with acute respiratory failure are often referred to the intensive care unit for ventilatory support. Available data showed that outcome of these patients is very poor and mechanical ventilation is mostly futile. Patients and their families should be informed about the prognosis, outcome and overall outlook before making decision about ventilation and organ support. Available outcome data should be used to develop institutional and professional guidelines to help in making these difficult decisions.

Entities:  

Mesh:

Year:  2008        PMID: 18635345     DOI: 10.1016/j.rmed.2008.06.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  30 in total

1.  Prognostic impact of high-flow nasal cannula oxygen supply in an ICU patient with pulmonary fibrosis complicated by acute respiratory failure.

Authors:  Alexandre Boyer; Frédéric Vargas; Maricke Delacre; Mélanie Saint-Léger; Benjamin Clouzeau; Gilles Hilbert; Didier Gruson
Journal:  Intensive Care Med       Date:  2010-09-18       Impact factor: 17.440

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Staging and outcome in acute exacerbation of idiopathic pulmonary fibrosis: are all limits and determinants under control?

Authors:  Antonio M Esquinas; Alejandro Ubeda Iglesias; Angela Reina González
Journal:  Lung       Date:  2014-10-14       Impact factor: 2.584

4.  The palliative care needs of patients with idiopathic pulmonary fibrosis: A qualitative study of patients and family caregivers.

Authors:  Kathleen Oare Lindell; Dio Kavalieratos; Kevin F Gibson; Laura Tycon; Margaret Rosenzweig
Journal:  Heart Lung       Date:  2016-11-18       Impact factor: 2.210

5.  Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection.

Authors:  Gregory A Zornetzer; Matthew B Frieman; Elizabeth Rosenzweig; Marcus J Korth; Carly Page; Ralph S Baric; Michael G Katze
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 6.  Brazilian recommendations of mechanical ventilation 2013. Part 2.

Authors: 
Journal:  J Bras Pneumol       Date:  2014-10       Impact factor: 2.624

7.  Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study.

Authors:  Jiro Ito; Kazuma Nagata; Takeshi Morimoto; Mariko Kogo; Daichi Fujimoto; Atsushi Nakagawa; Kojiro Otsuka; Keisuke Tomii
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

8.  Retrospective immunohistological study of autopsied lungs in patients with acute exacerbation of interstitial pneumonia managed with extracorporeal membrane oxygenation.

Authors:  Yoshiko Kida; Shinichiro Ohshimo; Michihito Kyo; Koji Hosokawa; Vishwa Jeet Amatya; Yukio Takeshima; Nobuaki Shime
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

9.  Systemic glucocorticoids plus cyclophosphamide for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective nationwide study.

Authors:  Shotaro Aso; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

10.  A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis.

Authors:  Claude Jourdan Le Saux; Philip Davy; Christopher Brampton; Seema S Ahuja; Steven Fauce; Pooja Shivshankar; Hieu Nguyen; Mahesh Ramaseshan; Robert Tressler; Zhu Pirot; Calvin B Harley; Richard Allsopp
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.